The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes to Hepatocellular Carcinoma Susceptibility

Yueh, Te‐Cheng; Tsao, Hao-Yuan; Chien, Wei-Ching; Tsai, Chia‐Wen; Pei, Jen-Sheng; Wu, Ming-Hsien; Chen, Chou-Pin; Chen, Chou-Chen; Wang, Zhihong; Mong, Mei-Chin; Yang, Ya‐Chen; Hung, Yi-Chih; Bau, Da‐Tian; Chang, Wen‐Yu

doi:10.21873/anticanres.16034

Cited by 4 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While different conclusions were obtained, Lin et al [11] reported that there was no correlation between CAV1 (rs7804372) polymorphism and gastric cancer susceptibility. Hsu et al [12] evaluated the relationships between six single nucleotide polymorphism of the CAV1 gene and hepatocellular cancer risk in a Taiwanese population. No significant association between rs7804372 polymorphism and hepatocellular cancer was observed.…”

Section: Discussionmentioning

confidence: 99%

“…[6] The carcinogenic role of CAV1 has been identified in several tumors, suggesting CAV1 as a novel therapeutic target for tumors. Several studies have explored the relationship between CAV1 polymorphisms and susceptibility to breast cancer, [7] esophageal carcinoma, [8] colorectal cancer, [9] gastric cancer, [10,11] hepatocellular, [12] and other cancers. [13,14] However, the results of the CAV1 rs7804372 (T29107A) polymorphism and susceptibility to digestive cancer remain controversial.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CAV1 rs7804372 (T29107A) polymorphism might be a potential risk for digestive cancers

Chen¹,

Zhang²,

Bai

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Caveolin-1 (CAV1) is an essential structural component of caveolae, regulates cellular processes through complex cellular signaling pathways, and influences tumorigenicity. However, the role of the CAV1 (rs7804372) polymorphism in digestive cancers remains inconclusive. The meta-analysis was performed to evaluate the effect of CAV1 polymorphism on digestive cancer susceptibility and to provide a basis for precise treatment. Methods: The databases of PubMed, EMBASE, Google Scholar and CNKI were used to retrieve the published studies on CAV1 (rs7804372) polymorphism and susceptibility to digestive cancers up to June 2020. Two researchers conducted study screening, data extraction, and methodological quality evaluation separately according to inclusion and exclusion criteria. Review Manager 5.3 software was used to conduct the meta-analysis. Results: Six case-control studies were enrolled, including 2477 patients with digestive cancers and 2477 healthy controls. The pooled results showed that the CAV1 rs7804372 (T29107A) polymorphism increased the risk of digestive cancer occurrence in the allele ( T vs. A : odds ratio (OR) 1.33, 95% confidence interval (CI): 1.15–1.53, P < .01), homozygous ( TT vs. AA : OR 1.72, 95% CI: 1.31–2.26, P < .01), heterozygous ( TA vs. AA : OR 1.47, 95% CI: 1.21–1.78, P < .01), dominant ( TT vs. TA + AA : OR 1.32, 95% CI: 1.18–1.48, P < .01), and recessive comparing models ( TT + TA vs. AA : OR 1.61, 95% CI: 1.26–2.07, P < .01). Conclusion: Our results indicate that the CAV1 (rs7804372) polymorphism may modify the occurrence of digestive cancers, and the presence of T allele or TT genotype of the CAV1 (rs7804372) may increase the risk of digestive cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

CAV1 rs7804372 (T29107A) polymorphism might be a potential risk for digestive cancers

Chen¹,

Zhang²,

Bai

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

“…MMP-2 rs243865 and rs2285053 genotyping. DNA was extracted from the whole blood of each participant as previously published (40)(41)(42). In the present study, the profiles of MMP-2 rs243865 and rs2285053 genotypes among 218 PCa and 436 controls were determined by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology.…”

Section: Methodsmentioning

confidence: 99%

“…The sequences of forward and reverse primers for MMP-2 rs243865 are: 5'-CTTCCTAGGCTGGT CCTTACTGA-3' and 5'-CTGAGACCTGAAGAGCTAAAGAGCT-3', and those for MMP-2 rs2285053 are 5'-GGATTCTTGGCTTGGC GCAGGA-3' and 5'-GGGGGCTGGGTAAAATGAGGCTG-3'. The primers for MMP-2 rs243865 and rs2285053 genotyping are the same as we have previously published (42,43). The PCR condition was set as: 5 min initial step at 94˚C; 40 cycles of 94˚C for 30 s, 55˚C for 30 s, and 72˚C for 30 s; and a final extension step at 72˚C for 10 min.…”

Section: Methodsmentioning

confidence: 99%

Association of Matrix Metalloproteinase-2 Genotypes With Prostate Cancer Risk

Liao

Huang

et al. 2022

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: Prostate cancer is one of the most commonly diagnosed malignancies among males, especially in Western populations. Matrix metalloproteinase-2 (MMP-2) plays a critical role in extracellular regulation and metastasis. However, its genotypes have seldom been examined among patients with prostate cancer (PCa). Therefore, the purpose of the study was to evaluate the association of genotypes at MMP-2 promoter -1306 (rs243865) and -735 (rs2285053) with PCa risk in a Taiwanese cohort. Materials and Methods: The profiles of MMP-2 rs243865 and rs2285053 genotypes were examined among 218 PCa patients and 436 healthy controls by polymerase chain reaction-restriction fragment length polymorphism methodologies. Results: The percentages of wildtype CC, and variant CT and TT genotypes on MMP-2 rs243865 were 88.5, 10.6, and 0.9% in the PCa case group and 85.6, 13.5, and 0.9% in the control group, respectively (p for trend=0.5544). The allelic frequency distribution showed that the variant T allele at MMP-2 rs24386 5 was not associated with PCa risk (p=0.3250). As for MMP-2 rs2285053, the results were also non-significant. In addition, there was no association between the genotypes of MMP-2 rs243865 or rs2285053 with age or smoking status on PCa risk. Conclusion: rs11568818 and rs11568819 at MMP-2 promoter region played minor roles in determining individual PCa risk.Prostate cancer (PCa) is the second most prevalent malignancy, and the fifth leading death-causing cancer among males worldwide, with about 1,414,000 newly diagnosed cases and 375,304 deaths in 2020 (1). According to global cancer statistics, PCa is the most frequently diagnosed cancer in 112 countries, and the leading death-causing malignancy in 48 countries including USA (2). According to world cancer statistics, PCa cases are predicted to continue to increase due to the trend of global aging (3). From the epidemiological viewpoint, black race, family cancer history, and aging, are three most well-known risk factors for PCa (4). In addition, fitness (5), diabetes mellitus (6), obesity (7), risky diet (8), and over-supplementation of vitamin E (9) may also contribute to the etiology of PCa. However, lack of targets in PCa therapy urge the identification of genetic markers.The extracellular matrix (ECM) is a meshwork of crosslinked macromolecules that form a dynamic scaffold outside of the cells. It provides homeostasis of the micro-environment, and its imbalances may associate with cancer progression and metastasis (10,11). Noticeably, matrix metalloproteinases (MMPs, also named matrix metallopeptidases or matrixins) play 343 *These Authors contributed equally to this study.

show abstract

“…Although the structure of MMP7 is the simplest in the MMPs family, with a size of only 19KDA after activation, it degrades a wide range of substrates, including extracellular matrix and nonextracellular matrix, which is conducive to tumor metastasis and invasion. With the deepening of research on MMP7 by researchers, it has been found that MMP7 is overexpressed in gastric cancer, liver cancer, and colon cancer [20][21][22] . More importantly, MMP7 is secreted by tumor cells themselves, while other members of the MMPs family are secreted by tumor stromal cells.…”

Section: Introductionmentioning

confidence: 99%

EGFR and MMP7 are important targets for gastric cancer metastasis

Ding,

Wan,

et al. 2023

Preprint

View full text Add to dashboard Cite

The invasion and metastasis of gastric cancer pose frequent clinical challenges following standard treatment. Investigating the molecular mechanisms underpinning gastric cancer invasion and metastasis constitutes a critical research area. This study aims to pinpoint potential target molecules involved in gastric cancer metastasis. After analyzing the TCGA database, we identified overexpression of EGFR and MMP7 in gastric adenocarcinoma, which correlates with unfavorable patient outcomes. Notably, MMP7 expression is closely linked to gastric adenocarcinoma metastasis. Immunohistochemical analysis of clinical gastric adenocarcinoma tissue samples confirmed the association of both EGFR and MMP7 with metastasis, aligning with the findings from bioinformatics analysis. Moreover, our immunohistochemical results revealed a positive correlation between EGFR and MMP7 expression, providing a foundational basis for future endeavors in searching for drug targets to prevent and treat gastric cancer invasion and metastasis.

show abstract

The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes to Hepatocellular Carcinoma Susceptibility

Cited by 4 publications

References 48 publications

CAV1 rs7804372 (T29107A) polymorphism might be a potential risk for digestive cancers

CAV1 rs7804372 (T29107A) polymorphism might be a potential risk for digestive cancers

Association of Matrix Metalloproteinase-2 Genotypes With Prostate Cancer Risk

EGFR and MMP7 are important targets for gastric cancer metastasis

Contact Info

Product

Resources

About